BGC20-761

In this article, we will explore the fascinating world of BGC20-761 and its implications on modern society. From its origins to its impact today, BGC20-761 has been the subject of debate, discussion and constant interest. Over the years, BGC20-761 has proven its relevance in various fields, from politics to science to popular culture. Through this comprehensive analysis, we will seek to better understand the importance of BGC20-761 in today's world and how it has shaped the way we think, act, and relate to the environment around us. Join us on this journey of discovery and reflection about BGC20-761.

BGC20-761
Identifiers
  • 2-(5-methoxy-2-phenyl-1H-indol-3-yl)-N,N-dimethylethanamine
CAS Number
PubChem CID
Chemical and physical data
FormulaC19H22N2O
Molar mass294.398 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=C(NC2=C1C=C(C=C2)OC)C3=CC=CC=C3
  • InChI=1S/C19H22N2O/c1-21(2)12-11-16-17-13-15(22-3)9-10-18(17)20-19(16)14-7-5-4-6-8-14/h4-10,13,20H,11-12H2,1-3H3
  • Key:VSGPGYWZVPDDSK-UHFFFAOYSA-N

BGC20-761 (5-MeO-2-phenyl-DMT, PMDT) is an experimental drug which acts as an antagonist of the 5-HT6, 5-HT2 family, and dopamine D2 receptors, with strongest affinity for 5-HT6. In animal studies it has antipsychotic-like effects, but also memory enhancing action attributed to its 5-HT6 affinity.[1][2][3]

See also

References

  1. ^ Mitchell ES, Hoplight BJ, Lear SP, Neumaier JF (March 2006). "BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism". Neuropharmacology. 50 (4): 412–420. doi:10.1016/j.neuropharm.2005.10.002. PMID 16298400.
  2. ^ Kendall I, Slotten HA, Codony X, Burgueño J, Pauwels PJ, Vela JM, et al. (February 2011). "E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat". Psychopharmacology. 213 (2–3): 413–430. doi:10.1007/s00213-010-1854-3. PMID 20405281.
  3. ^ Geldenhuys WJ, Van der Schyf CJ (September 2011). "Role of serotonin in Alzheimer's disease: a new therapeutic target?". CNS Drugs. 25 (9): 765–781. doi:10.2165/11590190-000000000-00000. PMID 21870888.